Table 4.
Inhibition of SARS-CoV-2 nsp13 helicase-associated activities by compounds.
| Compound | a IC50 (μM) Unwinding | b IC50 (μM) NTPase |
|---|---|---|
| Ceftaroline fosamil | >30 (100%) c | >30 (100%) |
| NADH | >30 (100%) | >30 (100%) |
| Polydatin | >30 (100%) | >30 (100%) |
| PF-03715455 | 3.02 ± 0.21 | 9.26 ± 1.93 |
| PF-00610355 | 22.4 ± 1.7 | >30 (100%) |
| SSYA10-001 | 2.3 ± 0.7 | ND d |
| Licoflavone C | 8.7 ± 1.3 | 20.9 ± 0.8 |
a Compound concentration required to inhibit the SARS-CoV-2 nsp13-associated unwinding activity by 50%; b Compound concentration required to inhibit the SARS-CoV-2 nsp13-associated ATPase activity by 50%; c Percentage of control measured in the presence of the highest tested compound concentration; d Not tested.